NRX PHARMACEUTICALS INC (NRXP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$3.49+1.75%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · NRXP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 121.7% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Worth watching into the next print: this name has erratic recent earnings surprises and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
NRXP — earnings miss
Dated 2026-08-17
Results of Operations and Financial Condition. On August 17, 2026, NRx Pharmaceuticals, Inc. (the “Company”) announced via press release its results for the second quarter ended June 30, 2026. A copy of the Company’s press release is hereby furnished and incorporated herein by reference as Exhibit 99.1.
Why it matters: Better operating income is important for financial health. Ongoing losses show there are still problems.
Supportive ifOperating income shows less than a 10% decline year over year in Q2 earnings.
Worry ifOperating income stays negative or drops more in Q2 earnings.
Why it matters: Finishing this will give needed money for operations and growth.
Supportive ifPublic offering closes with gross proceeds of at least $20 million.
Worry ifOffering fails to close or raises significantly less than $20 million.
Why it matters: If revenue keeps growing, it shows the company is doing well.
Supportive ifKetamine sales made over $1.5 million this quarter.
Worry ifKetamine sales were under $1 million this quarter.
Why it matters: NRX needs to follow rules to keep its listing and gain investor trust.
Supportive ifA public announcement shows NRX has met Nasdaq's compliance rules.
Worry ifMore delays or failures in meeting Nasdaq's compliance rules.
Why it matters: Addressing compliance is crucial for maintaining the company's listing status. Failure could lead to delisting.
Worry ifThe company says it meets Nasdaq listing rules.
Less concerning ifThe company does not meet compliance and faces delisting.
Why it matters: Good news on the ANDA could mean progress in getting approval. This is key for growth.
Supportive ifFDA confirms no major deficiencies in the ANDA for NRX-100.
Worry ifThe FDA finds major problems in the ANDA submission.
Why it matters: Positive feedback on the label update could speed up the approval process for NRX-100.
Supportive ifThe FDA confirms acceptance of the updated label for NRX-100.
Worry ifThe FDA requests further revisions or delays the label update.
Why it matters: The success of the public offering could provide needed capital for growth. Poor reception may signal investor concerns.
Watch forThe public offering is fully subscribed and raises at least $10 million.
Also watch forThe offering fails to attract enough investors, raising less than $5 million.
Why it matters: Making more money is very important. A good trend would show that management is doing well.
Supportive ifOperating income goes from -$6.5 million in Q2 2026 to a less negative amount.
Worry ifOperating income worsens or remains at -$6.5 million or worse.
Why it matters: Advancements in the NDA process could lead to quicker approval and market entry.
Supportive ifCompany submits the NDA for NRX-100 with Real World Evidence by the end of 2026.
Worry ifNDA submission is late or does not have enough proof.
Why it matters: Good results may grow the market for NRX-101 and show it works.
Watch forSPARC-TMS trial shows positive efficacy results for NRX-101 with robotic TMS.
Also watch forTrial results show no significant efficacy for NRX-101.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$277 on $10,000 · ±2.8% | How much price usually moves either way. |
| Bad day | $834 loss on $10,000 · 8.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,422 loss on $10,000 · 54.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.